Zobrazeno 1 - 10
of 23
pro vyhledávání: '"E. M Koltsova"'
Autor:
A. S. Pisaryuk, V. A. Zamarashkina, N. B. Safarova, N. M. Povalyaev, E. O. Kotova, U. I. Babukhina, E. M. Koltsova, Zh. D. Kobalava
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 18, Iss 3, Pp 320-331 (2022)
The issue of antithrombotic therapy in patients with infective endocarditis has been studied for over 75 years. During that time studying of pathogenesis of the disease and its embolic complications, lead to the introduction of the concept of “immu
Externí odkaz:
https://doaj.org/article/7f533ffdbcd84eb6b628c89c6f0ec14a
Publikováno v:
Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology. 17:12-19
Autor:
A N Balandina, E M Koltsova, T A Teterina, A G Yakovenko, E U Simonenko, A V Poletaev, I V Zorina, A M Shibeko, T A Vuimo, S A Yakovenko, F I Ataullakhanov
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0216724 (2019)
BACKGROUND:The shift towards hypercoagulation during in vitro fertilization (IVF) can lead to the impairment of embryo implantation and placental blood circulation, which is believed to be a factor in an unsuccessful IVF cycle. OBJECTIVES:To assess c
Externí odkaz:
https://doaj.org/article/48eb47e427004e1bb66d39f22002a536
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 20:191-198
Malignant neoplasms are characterized by the presence of the hemostasis system pathology, predisposing cancer patients to thrombohemorrhagic complications. The pathogenesis of cancer-associated coagulopathy is complex and involves a variety of mechan
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 20:147-155
The new coronavirus infection (currently classified as COVID-19), first identified in December 2019 in Wuhan, China, has contributed to a significant increase in global mortality. Coagulopathy is a common disorder in COVID-19 patients, which develops
Autor:
E. M. Koltsova, E. S. Kurkina
Publikováno v:
Computational Mathematics and Modeling
We develop a mathematical model of the coronavirus propagation in different countries (Brazil, India, US, Japan, Israel, Spain, Sweden), in the city of Moscow, and across the world. The pandemic spreads by a highly complex dynamics because it occurs
Autor:
E. M. Koltsova, Elizaveta I. Anastasova, Vladimir V. Vinogradov, Artur Y. Prilepskii, Andrey S. Drozdov
Publikováno v:
Journal of Sol-Gel Science and Technology. 95:771-782
Magnetic thrombolytic composites are a promising and rapidly developing class of nanostructured bioactive materials with plausible applications in cardiovascular diseases treatment. This class of nanoformulations can be applied to enhance the efficie
Autor:
A. L. Karavaeva, L. A. Timofeeva, S. N. Volkov, E. N. Balashova, N. M. Dashkevich, A. V. Filatov, M. B. Shamanova, O. S. Burova, E. M. Koltsova, O. S. Fedyanina, A. N. Khvastunova, S. A. Kuznetsova, A. E. Zadorozhnaya
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 17:11-16
Both the ratio of different leukocyte subgroup content and the leukocyte morphology in peripheral blood of newborns are important in diagnosis of several diseases including combined immunodeficiency and neonatal septicemia. There is a need for develo
Autor:
Mikhail A. Panteleev, Fazoil I. Ataullakhanov, Anna D. Kuprash, Natalya M. Dashkevich, E. M. Koltsova, Maria A. Kumskova, Anna N. Balandina, Sukesh C. Nair, Artem V. Chernyakov, Alok Srivastava, David M. Vardanyan
Publikováno v:
Platelets. 32(8)
In this work, we present a new method-Thrombodynamics-4D-for the assessment of both plasma and platelet contributions to clotting. Thrombodynamics-4D potentially allows for the determination of plasma or platelet disorders and the effects of various
Autor:
Fazly I Ataullakhanov, Elena A. Seregina, Ilya I. Serebriyskiy, Konstantin I Grischuk, E. M. Koltsova, Margarita A Shpilyuk, Gennady T Sukhih, Alexander V Poletaev, Natalia M. Dashkevich, Alexey V Pyregov, Anna N. Balandina
Publikováno v:
Journal of Perinatal Medicine. 46:251-260
Introduction: The incidence of venous thromboembolism (VTE) after cesarean section is up to 0.6%, and the widespread use of cesarean section draws attention to this group. The dosage and duration of low-molecular-weight heparin (LMWH) prophylaxis aft